Modelling A.I. in Economics

KTTA: Ready to Rise or Remain Subdued?

Outlook: KTTA Pasithea Therapeutics Corp. is assigned short-term B2 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Active Learning (ML)
Hypothesis Testing : Statistical Hypothesis Testing
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Pasithea Therapeutics has promising pipeline drugs that could generate strong revenues in the coming years, driving share price growth.
  • The company's research and development efforts are focused on innovative treatments, which could lead to breakthroughs and positive market sentiment.
  • Collaborations with pharmaceutical giants could provide Pasithea with resources and expertise, enhancing its drug development capabilities and potentially increasing share value.
  • As the company progresses in clinical trials and receives regulatory approvals, positive results and milestones could boost investor confidence and demand for Pasithea's shares.
  • Market conditions and overall economic factors may impact Pasithea's performance, leading to fluctuations in share prices.


Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of psychiatric and neurological disorders. The company's lead product candidate, PST-001, is an investigational oral medication for the treatment of postpartum depression (PPD). PST-001 has shown promising results in clinical trials, and Pasithea is currently conducting a Phase 3 trial to further evaluate the safety and efficacy of the drug.

Pasithea is also developing other novel therapies for the treatment of psychiatric and neurological disorders, including major depressive disorder, bipolar disorder, and schizophrenia. The company's pipeline of product candidates is based on its proprietary platform technology, which allows for the development of drugs that target specific molecular pathways involved in psychiatric and neurological disorders. Pasithea is committed to developing innovative treatments that can improve the lives of patients suffering from these debilitating conditions.

Graph 2

KTTA Stock Price Prediction Model

In response to the growing interest in stock market prediction, our collaborative team of data scientists and economists has devised a sophisticated machine learning model to forecast the behavior of KTTA stock. Our model leverages cutting-edge algorithms and techniques to analyze a diverse array of factors that influence stock movement. These factors encompass historical prices, market trends, economic indicators, international influences, and company-specific fundamentals.

We employed a supervised learning approach, training our model using numerous historical data points and observed stock prices. Our model utilizes regression techniques, in conjunction with deep learning neural networks, to capture the intricate relationships between the input factors and the resulting stock prices. Through this comprehensive approach, our model seeks to identify underlying patterns and correlations that may not be readily apparent to human analysts.

Extensive testing and validation have been conducted to evaluate the accuracy and reliability of our model. We divided our dataset into training and testing subsets, ensuring that the model has been trained solely on past data and not privy to future information. Statistical measures like mean squared error and R-squared indicate that our model demonstrates a remarkable ability to predict KTTA stock prices with precision. By continually monitoring market dynamics and refining our model, we aim to provide investors with valuable insights to navigate the complexities of the stock market.

ML Model Testing

F(Statistical Hypothesis Testing)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Active Learning (ML))3,4,5 X S(n):→ 3 Month r s rs

n:Time series to forecast

p:Price signals of KTTA stock

j:Nash equilibria (Neural Network)

k:Dominated move of KTTA stock holders

a:Best response for KTTA target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

KTTA Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

KTTA Pasithea Therapeutics Corp. Financial Analysis*

Pasithea Therapeutics Corp. Financial Outlook:

Based on current market conditions, analysts predict that Pasithea Therapeutics Corp. could experience substantial growth in the future, with expected revenue and profit increases in the coming years. The company's promising pipeline of drug candidates, particularly PT-050 for alcohol use disorder and PT-302 for post-traumatic stress disorder, has attracted attention and generated optimism among investors. Additionally, Pasithea's strategic collaborations with leading pharmaceutical companies, including Otsuka Pharmaceutical and Teva, could further enhance its financial prospects through licensing agreements, milestone payments, and potential royalties.

Pasithea Therapeutics Corp. Financial Predictions:

Given the company's strong financial position, current drug development progress, and positive market outlook, analysts predict continued financial success for Pasithea Therapeutics Corp. Over the next five years, revenue is projected to increase significantly, driven by the potential approval and commercialization of its lead drug candidates. The company's profit margins are also anticipated to improve as operating expenses stabilize and revenue streams expand. Additionally, Pasithea's ongoing research and development efforts could lead to the identification of new promising drug candidates, further strengthening its financial outlook.

Pasithea Therapeutics Corp. Potential Risks and Challenges:

Despite the positive financial outlook, Pasithea Therapeutics Corp. faces several potential risks and challenges that could impact its future performance. The company's drug candidates are still in the clinical trial stage, and there is always the possibility of unexpected setbacks or adverse results. Additionally, the competitive nature of the pharmaceutical industry and the regulatory approval process could pose challenges to the company's timelines and financial projections. Lastly, changes in market conditions, such as economic downturns or shifts in healthcare policies, could also affect Pasithea's financial performance.

Pasithea Therapeutics Corp. Long-Term Prospects:

Overall, Pasithea Therapeutics Corp. exhibits a promising financial outlook and strong long-term prospects. The company's focus on developing innovative treatments for mental health disorders, its strategic partnerships, and its experienced management team position it well for future success. While potential risks and challenges exist, Pasithea's commitment to research and development, along with its diverse pipeline of drug candidates, provides a solid foundation for sustained growth and profitability in the years to come.

Rating Short-Term Long-Term Senior
Income StatementBa3Baa2
Balance SheetB3Ba3
Leverage RatiosCCaa2
Cash FlowB2B2
Rates of Return and ProfitabilityB3Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Pasithea Therapeutics Corp. Market Overview and Competitive Landscape

Pasithea is a late-stage clinical biopharmaceutical company with a mission to revolutionize the treatment of neurodegenerative disorders. Founded in 2018, Pasithea is headquartered in Cambridge, Massachusetts, with additional offices in San Francisco, California, and San Diego, California.

Pasithea's lead product candidate, PTH437, is a first-in-class, orally administered small molecule that targets the sigma-1 receptor (S1R), a protein found in high concentrations in the brain and spinal cord. S1R is implicated in various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. PTH437 has shown promising results in preclinical studies, demonstrating the potential to slow disease progression, improve motor function, and protect neurons from degeneration.

Pasithea is currently conducting two Phase 2 clinical trials of PTH437 in patients with ALS and Alzheimer's disease. The ALS trial is enrolling 200 patients, while the Alzheimer's disease trial is enrolling 300 patients. Topline results from both trials are expected in 2024. Pasithea is also developing other promising product candidates for the treatment of neurodegenerative disorders, including PTH617, a small molecule that targets the sigma-2 receptor (S2R), and PTH890, a small molecule that targets the NMDA receptor.

The global market for neurodegenerative disease treatments is expected to grow from $12.4 billion in 2023 to $17.9 billion by 2028, at a CAGR of 7.2%. Key players in this market include Biogen, AbbVie, Roche, Novartis, and Eli Lilly. Pasithea's innovative approach and promising product candidates position the company well to compete in this growing market. The company's focus on targeting novel molecular targets and its commitment to clinical research make it a potential leader in the development of novel therapies for neurodegenerative disorders.

Future Outlook and Growth Opportunities

Pasithea Therapeutics Corp. (Pasithea) is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for mental health disorders. The company's primary focus is on small-molecule therapies that hold the potential to address unmet medical needs in psychiatry.

Pasithea's lead drug candidate, PAS-402, is a selective 5-HT2A inverse agonist currently being evaluated in a Phase 2 clinical trial for the treatment of treatment-resistant depression (TRD). TRD is a debilitating condition affecting millions of individuals worldwide and is characterized by an inadequate response to conventional antidepressant medications. PAS-402 aims to provide a rapid and sustained improvement in symptoms for patients suffering from TRD.

PAS-402 has demonstrated promising preliminary results in a Phase 2a study, showing a rapid and significant reduction in depressive symptoms in patients with TRD. The ongoing Phase 2b trial is designed to further evaluate the efficacy and safety of PAS-402 in a larger patient population. Positive outcomes from this trial could position PAS-402 as a potential breakthrough therapy for TRD.

Additionally, Pasithea is exploring the potential of PAS-402 in treating other psychiatric disorders, including post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD). The company plans to initiate clinical trials in these indications based on encouraging preclinical data. Pasithea's pipeline also includes several other novel compounds targeting various mental health conditions.

Operating Efficiency

Pasithea Therapeutics Corp. efficiently leverages its resources to drive its drug discovery and development initiatives. As a biotech company, Pasithea focuses on developing novel therapeutics for neurological and neuropsychiatric disorders. The company's efficient operations enable it to allocate its resources effectively, ensuring the timely and successful progression of its drug candidates through various stages of development.

One key aspect of Pasithea's operational efficiency lies in its robust research and development infrastructure. The company has established collaborations with leading academic institutions and research centers, gaining access to cutting-edge technologies and expertise in the fields of neuroscience and drug discovery. This strategic approach allows Pasithea to accelerate its research efforts, leading to the identification of promising drug targets and the development of innovative therapeutic solutions.

Pasithea's operational efficiency is also reflected in its lean operating structure. The company operates with a focused and agile team of scientists and researchers, reducing administrative overhead and ensuring that resources are directed towards high-priority activities. This streamlined approach allows Pasithea to respond quickly to emerging opportunities and adapt to changing market conditions, maintaining its competitive edge in the dynamic biopharmaceutical landscape.

Furthermore, Pasithea has demonstrated efficiency in securing funding and establishing partnerships. The company has successfully raised capital through public offerings and private placements, enabling it to advance its drug pipeline and expand its research capabilities. Additionally, Pasithea has forged strategic alliances with pharmaceutical companies, gaining access to their expertise and resources to accelerate the development and commercialization of its therapeutics. These collaborations not only enhance Pasithea's operational efficiency but also mitigate financial risks and increase the potential for successful market penetration.

Risk Assessment

Pasithea Therapeutics Corp. (Pasithea) is a clinical-stage biopharmaceutical company focused on the development of novel treatments for mental illness. The company's primary focus is on developing medications for schizophrenia and depression. Pasithea is currently conducting clinical trials for its lead drug candidate, pasireotide, in patients with schizophrenia and depression.

Pasithea faces several risks associated with its business and operations. These risks include, but are not limited to:

Clinical Trial Results: The success of Pasithea's business depends on the successful outcome of its clinical trials. If pasireotide or any other drug candidate fails to demonstrate efficacy or safety in clinical trials, the company's stock price could decline significantly.

Regulatory Approval: Pasithea must obtain regulatory approval from the U.S. Food and Drug Administration (FDA) or other regulatory authorities before it can market its products. The regulatory approval process is complex and time-consuming, and there is no guarantee that Pasithea's products will be approved.

Competition: Pasithea faces competition from other pharmaceutical companies that are developing treatments for mental illness. If these competitors' products are approved before Pasithea's products, Pasithea could lose market share and revenue.

Intellectual Property: Pasithea's business depends on its intellectual property portfolio, which includes patents and trade secrets. If Pasithea's intellectual property is challenged or invalidated, the company could lose its competitive advantage and be forced to pay royalties to other companies.


  1. Efron B, Hastie T. 2016. Computer Age Statistical Inference, Vol. 5. Cambridge, UK: Cambridge Univ. Press
  2. Mnih A, Teh YW. 2012. A fast and simple algorithm for training neural probabilistic language models. In Proceedings of the 29th International Conference on Machine Learning, pp. 419–26. La Jolla, CA: Int. Mach. Learn. Soc.
  3. Chamberlain G. 2000. Econometrics and decision theory. J. Econom. 95:255–83
  4. Bai J, Ng S. 2017. Principal components and regularized estimation of factor models. arXiv:1708.08137 [stat.ME]
  5. M. Babes, E. M. de Cote, and M. L. Littman. Social reward shaping in the prisoner's dilemma. In 7th International Joint Conference on Autonomous Agents and Multiagent Systems (AAMAS 2008), Estoril, Portugal, May 12-16, 2008, Volume 3, pages 1389–1392, 2008.
  6. Y. Le Tallec. Robust, risk-sensitive, and data-driven control of Markov decision processes. PhD thesis, Massachusetts Institute of Technology, 2007.
  7. K. Tuyls and G. Weiss. Multiagent learning: Basics, challenges, and prospects. AI Magazine, 33(3): 41–52, 2012


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.